USA - engelska - NLM (National Library of Medicine)

remedyrepack inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - 1. indications progestin-only oral contraceptives are indicated for the prevention of pregnancy. 2. efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. method (1) % of women experiencing an unintended pregnancy within the first year of use % of women continuing use at one year * typical use † (2) perfect use ‡ (3) (4) no method § 85 85 spermicides ¶ 28 18 42 fertility awareness-based methods 24 47    standard days method # 5       two day method # 4    ovulation method # 3    symptothermal # 0.4 withdrawal 22 4 46 sponge 36    parous women 24 20    nulliparous women 12 9 condom Þ    female (fc) 21 5 41    male 18 2 4

USA - engelska - NLM (National Library of Medicine)

aurobindo pharma limited - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - 1.       indications  progestin-only oral contraceptives are indicated for the prevention of pregnancy.  2.      efficacy if used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. however, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. table 1 lists the pregnancy rates for users of all major methods of contraception. emergency contraception: emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.9 (see chapter 6.). lactational amenorrhea method: lam is a highly effective, temporary method of contraception.10 (see chapter 18.) source: trussell j. contraceptive efficacy. in hatcher ra, trussell j, nelson al, cates w, kowal d, policar m. contraceptive techology: twentieth revised edition. new york ny: ardent media, 2011. ——————————————————————————————————————————————————————————————————— notes: 1       among typical couples who initia

Australien - engelska - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - vismodegib -

Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - vismodegib 150mg;   - capsule - 150 mg - active: vismodegib 150mg   excipient: gelatin iron oxide black iron oxide red lactose monohydrate magnesium stearate microcrystalline cellulose opacode black s-1-17822 opacode black s-1-17823 povidone purified talc sodium laurilsulfate sodium starch glycolate titanium dioxide - indicated for the treatment of adult patients with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma where surgery and/or radiation therapy are not appropriate.